Waterdrop (WDH) Q2 2026 earnings review
Top-Line Surges on Marketing Spree, but Profits Contract
Waterdrop delivered a massive 72.8% YoY revenue increase, driven entirely by its Insurance segment. However, management's claim of 'strengthening profitability' is directly contradicted by the bottom line. Net Income fell 10.3% YoY, reversing the positive growth trajectory seen in FY25. The culprit is an aggressive user acquisition strategy: Sales & Marketing expenses skyrocketed 220.7% YoY. While the company is successfully buying revenue growth, the collapse in net margins raises serious concerns about the sustainability of this strategy and the true organic demand for its services.
🐂 Bull Case
Insurance-related income grew an impressive 80.5% YoY to RMB 1.33B. The rollout of new products like 'Rongyi Bao' and AI-driven sales tools are effectively converting traffic into premiums.
With RMB 2.65B in cash, the company authorized a new $50M share repurchase program and declared a $10.8M dividend, signaling confidence in liquidity despite heavy near-term marketing investments.
🐻 Bear Case
The 72.8% revenue growth required a 220.7% increase in Sales & Marketing spend. The resulting margin compression pushed GAAP Net Income down 10.3% YoY, proving this growth is highly dilutive.
Medical Crowdfunding service fees declined 5.7% YoY to RMB 63.6M, confirming the segment remains a lagging, non-growth component of the business.
⚖️ Verdict: 🔴
Bearish. While top-line growth is optically spectacular, the underlying unit economics are deteriorating. Buying revenue through 220%+ increases in marketing spend while net income shrinks is not a sustainable algorithm for value creation.
Key Themes
Exploding S&M Expenses Crush Net Margins
Management's narrative highlights 'improving operating performance,' but the data shows accelerating margin compression. Sales & Marketing expenses hit RMB 637.5M, a staggering 220.7% YoY jump driven by third-party traffic channels. This aggressive customer acquisition completely wiped out the bottom-line benefits of a 72.8% revenue surge, causing Net Income to decline 10.3% YoY to RMB 125.8M. The company is trading profitability for scale.
AI Enhancing Insurance Conversions
The company's 'AI-native' transformation is showing tangible operational results. The 'AI Medical Insurance Expert' drove a 25.6% sequential increase in facilitated premiums. The 'KEYI.AI' underwriting assistant has processed over 13,000 inquiries, and the 'AI Super Pre-Sales Assistant' saw a 50% QoQ increase in users served. This technological leverage is crucial for optimizing the massive influx of new top-of-funnel traffic.
Product Innovation: Rongyi Bao
A key growth driver this quarter was the launch of 'Rongyi Bao,' marketed as the industry's first long-term critical illness insurance requiring no health disclosure with a five-year guaranteed renewability. This low-friction onboarding product directly contributed to a 33.4% sequential growth in long-term premiums.
Crowdfunding Continues to Lag
The Medical Crowdfunding segment remains the definitive laggard. Revenue decelerated further, dropping 5.7% YoY to RMB 63.6M. While the company integrated new AI-powered risk controls to verify assets and prevent fraud, this segment is strictly functioning as a top-of-funnel brand asset rather than a financial growth engine.
Digital Clinical Trials Expansion
The E-Find platform continues to scale steadily, enrolling 1,540 patients and partnering with 255 pharmaceutical companies and CROs in Q2. Revenue reached RMB 35.2M (+26.8% YoY). While still a small portion of the overall revenue mix, it remains a high-margin, fast-growing adjacent vertical.
Other KPIs
Accelerating. Up 80.5% YoY, serving as the overwhelming engine for the company's 72.8% total revenue growth. This was fueled by a massive influx of third-party traffic spending and improved AI conversion tools.
Decreased from RMB 3.25B at the end of FY25. Despite the decline, the balance sheet remains robust enough to authorize the newly announced $50M share repurchase program over the next 12 months, running alongside the $10.8M cash dividend.
Guidance
Authorized for the next 12-month period through September 2027. This replaces prior completed authorizations and signals management's intent to aggressively support the stock price amidst heavy operating investments.
The Board approved a dividend of US$0.03 per ADS. Maintaining the dividend payout while simultaneously ramping up S&M expenses highlights management's dual-mandate of buying growth while pacifying yield-focused investors.
Key Questions
Sustainability of S&M Strategy
With Sales & Marketing up 220% YoY compared to Revenue up 73%, the Customer Acquisition Cost (CAC) is clearly spiking. What is the target payback period for these new cohorts, and at what point will the company taper this spend to allow Net Income to recover?
Transparency on Retention
You are acquiring users aggressively through third-party channels. What is the early data on renewal rates and cross-selling for this specific cohort compared to users acquired organically in previous years?
Crowdfunding Segment Future
With crowdfunding revenue shrinking YoY, is there a strategic plan to return this segment to growth, or is it strictly being managed as a breakeven loss-leader to feed the Insurance ecosystem?
Analyst Engagement
The company has established a pattern of omitting Q&A sessions from earnings calls. Given the massive strategic shift toward un-profitable, marketing-driven revenue growth, when will management open the floor to external scrutiny?